Skip navigation

Empower

Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer or why it might be common in their family.

Empower tests up to 53 genes associated with risk for common hereditary cancers using blood or saliva samples. Results are delivered within 2-3 weeks.

The Empower Hereditary Cancer Test is Designed with Your Practice in Mind

Four panel options with up to 53 genes across eight common hereditary cancer types

BRCA1 & BRCA2

Genes: BRCA1, BRCA2

Breast, Ovarian, Endometrial cancers and Lynch Syndrome genes

Additional Genes: ATM, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53

Most commonly screened-for, actionable hereditary cancer genes across 8 cancer types

Additional Genes: APC, AXIN2, BAP1, BARD1, BMPR1A, CDK4, CDKN2A, GALNT12, GREM1, HOXB13, MEN1, MITF, MSH3, MUTYH, NTHL1, POLD1, POLE, RNF43, RPS20, SMAD4, VHL

Includes multi-cancer panel plus additional genes with emerging evidence of elevated cancer risks

Additional Genes: CTNNA1, DICER1, KIT, MRE11, PDGFRA, RAD50, SDHA, SDHB, SDHC, SDHD, SMARCA4, TSC1, TSC2

Patient management recommendations based on medical guidelines

Actionable reports to guide next steps, including:

  • Screenings that detect cancer at its earliest, most treatable stage
  • Risk-reducing medications and surgeries
  • Surgical or therapeutic decisions for patients diagnosed with cancer
  • Informing family members to help them proactively manage hereditary cancer risk

Tyrer-Cuzick breast cancer risk results offer further risk refinement for patients with a negative result

  • Patients without a breast cancer-related gene mutation may still have increased risk for breast cancer based on their family cancer history and estrogen exposure over their lifetime.
  • Patients with ≥20% remaining lifetime breast cancer risk qualify for insurance coverage for preventive screenings including annual breast MRI surveillance in addition to an annual mammogram.
  • Tyrer-Cuzick evaluations are recommended by medical guidelines to calculate a woman’s breast cancer risk in the next 5 years and over the course of her lifetime.
  • Empower reports offer clear medical management information based on genetic and family history risk.
EMP-clin-Physian-portal

Natera is committed to patient affordability

Natera is proud to be an in-network provider with most health plans, including Aetna, Anthem, Cigna, and UnitedHealthcare.

 

For patients without adequate insurance coverage, Natera also offers self-pay pricing and compassionate care options.

EMP-clin-high-risk

Disclaimers : Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, et al. Genet Med. Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. 2015 Jan;17(1):43–50. Patel SG, Ahnen DJ, Kinney AY, et al. Am J Gastroenterol. Knowledge and uptake of genetic counseling and colonoscopic screening among individuals at increased risk for lynch syndrome and their endoscopists from the family health promotion project. 2016 Feb;111(2):285-93.

Many patients at high risk for hereditary cancer are not tested

When to consider hereditary cancer testing

EMP_Clin_1-50 years or younger

Personal or family history of cancer at age 50 or younger

EMP_Clin_2-different cancer

Personal or family history of ovarian, male breast or pancreatic cancer

EMP_Clin_3-multiple

Multiple cancers or tumors on the same side of the family

EMP_Clin_4-Ashkenazi ancestry

Ashkenazi ancestry

EMP_Clin_5-Cancer patient

Your patient is concerned about other familial cancer patterns

Is Empower right for you?

We’re here to help you find out